Romanian Journal of Pediatrics Logo
  • Home
  • Aims & Scope
  • Standards
    • Editorial policies
    • Instructions for authors
    • Peer review process
    • Guidelines for Reviewers
    • Ethics and Malpractice policies
    • Official Journal’s protocols & statements
    • Open Access
    • Fees
  • Editorial Council
  • Peer Review Council
  • EMC | CME
  • How to
  • SUBSCRIBE
  • Menu

Arhiva autor

  • About
  • Latest Posts

R. Muller

Latest posts by R. Muller (see all)

  • Mycofenolate mofetil versus cyclophosphamide for steroid-resistant nephrotic syndrome in children - 04/08/2015
  • MYCOFENOLATUL DE MOFETIL VERSUS CICLOFOSFAMIDA IN SINDROMUL NEFROTIC CORTICOREZISTENT LA COPII - 04/08/2015

Articole semnate de acelasi autor in Revista Romana de Pediatrie:

Mycofenolate mofetil versus cyclophosphamide for steroid-resistant nephrotic syndrome in children

SELECT ISSUE

Revista Romana de PEDIATRIE | Volumul LX, Nr. 2, An 2011
ISSN 1454-0398  |  e-ISSN 2069-6175
ISSN-L 1454-0398
DOI: 10.37897/RJP

Indexed

DOI - Crossref
Similarity Check by iThenticate, worldwide No 1 professional plagiarism checking system
DOAJ
Scopus
NLM Catalog
Ebsco Host - Medline
Google Academic
Semantic Scholar

HIGHLIGHTS

National Awards “Science and Research”

NEW! RJP has announced the annually National Award for "Science and Research" for the best scientific articles published throughout the year in the official journal.

ICMJE- Recommendations

Read the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals.

Promoting Global Health

The published medical research literature is a global public good. Medical journal editors have a social responsibility to promote global health by publishing, whenever possible, research that furthers health worldwide.

Mycofenolate mofetil versus cyclophosphamide for steroid-resistant nephrotic syndrome in children

Florentina Cucer, Ingrith Miron, Mihaela Munteanu, Codruţa Iliescu Haliţchi, R. Muller, R. Russu, Anca Ivanov, Doina Mihaila and O. Brumariu

ABSTRACT

The management of patients with steroid-resistant nephrotic syndrome is difficult. We report our experience on treatment with Mycophenolate mofetil versus Cyclophosphamide, in a retrospective analysis of 54 cases of idiopathic steroid-resistant nephrotic syndrome with different histological aspects. The complete and sustained remission rate was 50% for Mycophenolate, which confirm the efficacy of treatment, higher than with Cyclophosphamide (39.53%).

Key words: nephrotic syndrome, mycophenolate mofetil, cyclophosphamide, steroid-resistancy

Full text | PDF

Florentina Cucer

MYCOFENOLATUL DE MOFETIL VERSUS CICLOFOSFAMIDA IN SINDROMUL NEFROTIC CORTICOREZISTENT LA COPII

SELECT ISSUE

Revista Romana de PEDIATRIE | Volumul LX, Nr. 2, An 2011
ISSN 1454-0398  |  e-ISSN 2069-6175
ISSN-L 1454-0398
DOI: 10.37897/RJP

Indexed

DOI - Crossref
Similarity Check by iThenticate, worldwide No 1 professional plagiarism checking system
DOAJ
Scopus
NLM Catalog
Ebsco Host - Medline
Google Academic
Semantic Scholar

HIGHLIGHTS

National Awards “Science and Research”

NEW! RJP has announced the annually National Award for "Science and Research" for the best scientific articles published throughout the year in the official journal.

ICMJE- Recommendations

Read the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals.

Promoting Global Health

The published medical research literature is a global public good. Medical journal editors have a social responsibility to promote global health by publishing, whenever possible, research that furthers health worldwide.

MYCOFENOLATUL DE MOFETIL VERSUS CICLOFOSFAMIDA IN SINDROMUL NEFROTIC CORTICOREZISTENT LA COPII

Florentina Cucer, Ingrith Miron, Mihaela Munteanu, Codruţa Iliescu Haliţchi, R. Muller, R. Russu, Anca Ivanov, Doina Mihaila and O. Brumariu

REZUMAT

Managementul pacienţilor cu sindrom nefrotic corticorezistent (SNCR) este dificil. Vom prezenta experienţa noastrǎ în tratamentul cu Mycofenolat de mofetil versus Ciclofosfamidǎ, într-o analizǎ retrospectivǎ a 54 de cazuri cu sindrom nefrotic corticoresistent idiopatic cu aspecte histologice diferite. Rata remisiunii complete şi susţinute a fost de 50% pentru Mycofenolat, ceea ce confirmǎ eficienţa tratamentului, aceastǎ ratǎ fiind mai mare decât în tratamentul cu Ciclofosfamidǎ (39,53%).

Cuvinte cheie: sindrom nefrotic, mycofenolat de mofetil, ciclofosfamidă, corticorezistenţǎ

Full text | PDF

Florentina Cucer


SEARCH

STANDARDE

  • Instructions for authors
  • Peer review process

Submit article

Submit your article to the journal by using the form here:

Submit

Subscriptions

To receive the Ro Journal of PEDIATRICS click here:

SUBSCRIBE
Publicare-RRPedia
Abonare_RRPedia

Partners

Partners logo

plic-maileditor@rjp.com.ro

Subscribe to the Newsletter

Articles from the journal are licensed under a 
Creative Commons Attribution 4.0 International License

 Terms & Conditions

Open Access Statement

Publisher : AMALTEA Medical Publishing House

The intended audience of the site content is professionals from the medical and pharmaceutical community.
This site does not collect any personal data nor does it use cookies that might obtain such data from your browser. [ info ]
Agree
Contact

Submit ARTICLE
E-mail: editor@rjp.com.ro  |  Mobile: +4 0742.155.512, M-F 09.00-18.00 EET

SUBSCRIPTIONS
E-mail: info@amaltea.ro |  Mobile: +4 0742.155.511, M-F 09.00-18.00 EET